Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(158 produits)
- ATM/ATR(71 produits)
- ADN-PK(51 produits)
- EGFR(572 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(242 produits)
- S6 Kinase(9 produits)
- gsk-3(112 produits)
- mTOR(144 produits)
Affichez 2 plus de sous-catégories
1038 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
BX-320
CAS :<p>BX-320, a PDK1 inhibitor (IC50=30nM), selectively blocks Akt/p70S6K1 phosphorylation, induces apoptosis, and inhibits cancer cell growth.</p>Formule :C23H31BrN8O3Couleur et forme :SolidMasse moléculaire :547.45BEBT-109
CAS :<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Formule :C27H32N8O3Degré de pureté :97.26%Couleur et forme :SolidMasse moléculaire :516.6EGFR-IN-30
CAS :<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formule :C28H33BrN7O2PCouleur et forme :SolidMasse moléculaire :610.49EGFR-IN-61
CAS :<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Formule :C33H37ClN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :629.15EGFR-IN-85
CAS :<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Formule :C26H30N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :486.57JGK-068S
CAS :<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formule :C22H23BrFN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :488.35PI3K/mTOR Inhibitor-12
CAS :<p>PI3K/mTOR Inhibitor-12: oral, potent, selective; IC50: PI3Kα 0.06 nM, mTOR 3.12 nM; strong antitumor; less liver toxicity.</p>Formule :C27H27F2N9O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :611.62Simotinib
CAS :<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formule :C25H26ClFN4O4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :500.95EGFR/CSC-IN-1
CAS :<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Formule :C54H54Cl2FN7O7S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1067.082′-Thioadenosine
CAS :<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Formule :C10H13N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :283.31DZD1516
CAS :<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formule :C28H27F2N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :547.56EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formule :C34H39ClFN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :632.17GSK-3β inhibitor 8
CAS :<p>GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine</p>Formule :C20H20ClN5OSDegré de pureté :98.46%Couleur et forme :SolidMasse moléculaire :413.92EGFR-IN-36
CAS :<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97EGFR-IN-32
CAS :<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formule :C31H34N6O3Couleur et forme :SolidMasse moléculaire :538.64AMPK-α1β1γ1 activator 1
CAS :<p>AMPK-α1β1γ1 activator 1 (M1), an acyl glucuronide metabolite derived from an Indole-3-carboxylic Acid-based AMPK activator, selectively activates the β1</p>Formule :C25H24ClNO9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.91EGFR-IN-87
CAS :<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61EGFR-IN-1 hydrochloride
CAS :<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formule :C28H31ClN6O4Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :551.04BGB-8035
CAS :<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formule :C24H31N5O4Degré de pureté :96.74%Couleur et forme :SolidMasse moléculaire :453.53EGFR/ErbB-2 inhibitor-1
CAS :<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formule :C23H15ClFN3OS2Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :467.97Sevabertinib
CAS :<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formule :C24H25ClN4O5Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :484.93Rheb inhibitor NR1
CAS :<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Formule :C25H19BrCl2N2O3SDegré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :578.3PI3K-IN-54
CAS :<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Formule :C20H24F2N8O3Degré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :462.45GSK-F1
CAS :<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Formule :C27H18F5N5O4SDegré de pureté :97.03%Couleur et forme :SolidMasse moléculaire :603.52PF-04979064
CAS :<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Formule :C24H26N6O3Degré de pureté :98.20% - ≥98%Couleur et forme :SolidMasse moléculaire :446.5PKI-402
CAS :<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Formule :C29H34N10O3Degré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :570.65GSK-3 inhibitor 1
CAS :<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Formule :C22H17ClFN5O2Degré de pureté :98.42%Couleur et forme :SolidMasse moléculaire :437.85EGFR-IN-8
CAS :<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02GDC-0349
CAS :<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Formule :C24H32N6O3Degré de pureté :96.00% - 98.17%Couleur et forme :SolidMasse moléculaire :452.55GLPG3312
CAS :<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23DNA-PK-IN-15
CAS :<p>DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.</p>Formule :C23H23N9OCouleur et forme :SolidMasse moléculaire :441.49HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Couleur et forme :SolidEGFR-IN-147
CAS :<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formule :C24H15FO3Couleur et forme :SolidMasse moléculaire :370.37EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57LAS195319
CAS :<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Formule :C29H26N10O3SCouleur et forme :SolidMasse moléculaire :594.65EGFR-IN-23
CAS :<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68iMDK quarterhydrate
<p>iMDK quarterhydrate, PI3K inhibitor, blocks MDK growth; suppresses NSCLC safely with MEK inhibitor.</p>Formule :C21H15FN2O3SCouleur et forme :SolidMasse moléculaire :380.91ES-072
CAS :<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61Tesevatinib tosylate
CAS :<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59PI3Kδ-IN-23
CAS :<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Formule :C30H30N6O5Couleur et forme :SolidMasse moléculaire :554.596DNA-PK-IN-6
CAS :<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Formule :C19H21N7OCouleur et forme :SolidMasse moléculaire :363.42EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.975-Bromo-3-indoxylacetate
CAS :<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Formule :C10H8BrNO2Couleur et forme :SolidMasse moléculaire :254.08HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23DNA-PK-IN-8
CAS :<p>DNA-PK-IN-8: Potent, selective oral DNA-PK inhibitor, IC50 = 0.8 nM, boosts anti-cancer effects with Doxorubicin.</p>Formule :C19H22N8O2Couleur et forme :SolidMasse moléculaire :394.43
